John Byon
Chief Medical Officer Imugene
Seminars
Tuesday 15th September 2026
Enhancing CAR-T Persistence & Outcomes through IL-2–Driven Optimization & Strategic Combination Therapy
9:30 am
- Demonstrating how low-dose IL-2 postinfusion improves CAR-T pharmacokinetics, persistence, and clinical durability without additional cell engineering
- Discussing combination-based optimization as a practical pathway to overcoming first-generation allo-CAR-T limitations
- Exploring early clinical direction for integrating BTK inhibition to further enhance efficacy and long-term responses
